Renal, Urology Expert Commentary, Case Studies & Opinions

Commentary

COMMENTARY

Lymphovascular Invasion Helps Predict Post-RP Biochemical Recurrence

Basic Science: The Tail That Wags the RCC Dog

I recently had reason to survey the progress made in renal cell cancer (RCC) over the last 70 or more years. In 1950, a patient who presented with metastatic RCC had a 0%-5% overall response rate (ORR) to the therapies of the time, with an anticipated overall survival (OS) of approximately 10 months. By 2005,…
Home HD improves cardiovascular outcomes.

Kidney Health Initiative Offers Promise, Unknowns

Many nephrologists and other healthcare providers (HCPs) have enthusiastically embraced the July 10 presidential executive order titled, “Advancing American Kidney Health Initiative.” The 3 main components include a reduction in the end-stage renal disease (ESRD) rate by 25% by 2030; a substantial increase in home dialysis so that 80% of new ESRD patients can receive…
Ongoing studies are expected to provide information about how to sequence cabozantinib in clinical p

RCC in Advanced CKD: A Transplant Dilemma

Non-dialysis patients with advanced CKD diagnosed with renal malignancies grapple with the dual threat of renal failure and cancer progression. When  choosing between functional or oncologic risks, many patients will ask about renal transplantation. Discussions of  this option are complicated by statistical realities: According to UNOS, of  nearly 1 million solid organ transplants performed over…

Could Potassium-Restricted Diets Come to an End?

Hyperkalemia, defined as a serum potassium level above 5.3 mmol/L, develops in many patients with chronic kidney disease (CKD). The abnormality can precipitate serious adverse outcomes, including dysrhythmias and sudden cardiac death, so patients with elevated blood potassium levels may be referred to emergency departments or urgent care facilities for immediate therapy. As a result,…

That Nebulous Concept Called Standard of Care

During a session at the 2019 Genitourinary Cancers Symposium (GUCS) held recently in San Francisco, researchers presented findings from phase 3 studies showing that immunotherapy-based combination regimens are superior to sunitinib alone at improving progression-free survival among patients with previously untreated advanced kidney cancer. One study demonstrated improved overall survival. The study presenters concluded that…